BACKGROUND/AIM - Renal cell carcinoma (RCC) accounts for approximately 3% of all cancer-related mortalities worldwide and the risk factors for the development of RCC have not yet been fully elucidated. Mounting proteomic evidence suggests that inflammatory process plays a role in RCC etiology and interleukin-10 (IL-10) is an important immunosuppressive cytokine.
However, little is known on the contribution of IL-10 genotypes to RCC. This study aimed at evaluating the contribution of IL-10 promoter A-1082G (rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic polymorphisms to the risk of RCC in Taiwan.
MATERIALS AND METHODS - Associations of the three IL-10 polymorphic genotypes with the risk of RCC were examined among 92 RCC patients and 580 age- and gender-matched cancer-free controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology.
RESULTS - The pilot results showed that the percentages of TT and TC for IL-10 T-819C genotypes were significantly higher in the RCC patient group than those in the healthy control group. The CC genotype carriers were of lower risk for RCC (odds ratio (OR)=0.33, 95% confidence interval (CI)=0.12-0.93, p=0.0369). There is no difference in the distribution of A-1082G or A-592C genotype between the RCC and control groups.
CONCLUSIONS - The CC genotype of IL-10 T-819C genotype may have a protective effect on RCC risk in Taiwan. Further investigation with larger sample size in addition to genotype-phenotype correlation and intracellular mechanisms are our future work.
Anticancer research. 2016 May [Epub]
Wen-Shin Chang, Cheng-Hsi Liao, Chia-Wen Tsai, Pei-Shin Hu, Hsi-Chin Wu, Shih-Wei Hsu, Hong-Xue Ji, Chieh-Lun Hsiao, DA-Tian Bau
Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C. National Defense Medical Center, Taipei, Taiwan, R.O.C., Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C., Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C., Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C., Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C. National Defense Medical Center, Taipei, Taiwan, R.O.C., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C. Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C. Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.